Indian Journal of Medical and Paediatric Oncology, Table of Contents CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2019; 40(01): 130-131DOI: 10.4103/ijmpo.ijmpo_67_19 Drug Review Drug review: Carfilzomib Authors Author Affiliations Prasanth Ganesan Department of Medical Oncology, JIPMER, Puducherry, India Recommend Article Abstract Abstract Carfilzomib is a second generation proteasome inhibitor approved for use in relapsed/ refractory multiple myeloma. The mechanism of action, usage, toxicity and key trials involving this agent are briefly reviewed here. Keywords KeywordsCarfilzomib - proteasome inhibitor - multiple myeloma Full Text References References 1 Kortuem KM, Stewart AK. Carfilzomib. Blood 2013; 121: 893-7 2 Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142-52 3 Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): An interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 2017; 18: 1327-37 4 Carfilzomib: highlights of Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf. [Last accessed on 2019 Mar 04]. 5 Landgren Landgren. editor. Carfilzomib-Lenalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Results from the Prospective, Longitudinal, Observational Commpass Study. 60th Annual Meeting and Exposition. ASH; 1-4 December, 2018. 6 Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K. et al. nce weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): Interim analysis results of a randomised, phase 3 study. Lancet Oncol 2018; 19: 953-64
